| Name | Title | Contact Details |
|---|
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.
Elucida Oncology, Inc., is a clinical development stage company based on proprietary ultra-small C-Dot technology to find, see and treat an array of solid tumor cancers. Developed and clinically translated by Memorial Sloan-Kettering Cancer Center and Cornell University, C-Dots have published human safety and tumor-specific clinical data. Elucida Oncology is currently progressing through a broad clinical trial program while continuing to drive a future portfolio through ongoing innovation.
Ordaos is a human-enabled, machine-driven drug design company.
Chelsea Therapeutics is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marligen Biosciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.